Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis

被引:21
作者
Diao, Zongli [1 ]
Liu, Xu [1 ]
Qian, Linxue [2 ]
Liu, Jing [1 ]
Liu, Sha [1 ]
Liu, Wenhu [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, 95 Yong An Rd, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Ultrasound, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Efficacy; microwave ablation; parathyroidectomy; predictor; secondary hyperparathyroidism; CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; DIALYSIS PATIENTS; SUBTOTAL PARATHYROIDECTOMY; RADIOFREQUENCY ABLATION; LASER-ABLATION; SURVIVAL; GUIDELINES; MANAGEMENT; CARCINOMA;
D O I
10.1080/02656736.2016.1194485
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Microwave ablation (MWA) can be used to treat severe secondary hyperparathyroidism; however, its efficacy and the predictor of its efficacy are unclear. In this retrospective study we determined the predictor of efficacy of MWA and compared the efficacy of MWA and parathyroidectomy. Materials and methods: Patients with severe secondary hyperparathyroidism who had received MWA or parathyroidectomy were enrolled in the study. Participants with MWA were divided into response and no response groups based on efficacy. Possible predictors were analysed using logistic regression to determine efficacy predictors. The participants were divided into MWA and parathyroidectomy groups, and the efficacy (including rates of achieving recommended goals for intact parathyroid hormone (iPTH), calcium, and phosphorus levels) were compared between the two groups. Results: Thirty-one participants were enrolled for predictor analysis. Only baseline iPTH level predicted efficacy (OR 0.997, P = 0.018). The optimal threshold value of iPTH for predicting efficacy was 1493.5 pg/mL. To compare efficacy, 30 patients were enrolled in MWA (18/30) and parathyroidectomy (12/30) groups. The rates of achieving recommended goals for iPTH levels varied between 0 and 60%; a significant difference was found between the groups at 5 months (P = 0.01). However, in the parathyroidectomy group, the iPTH level and rate of iPTH <124 pg/mL (lower limit of target range) were significantly lower than in the MWA group after treatment (40-75% versus 0-16.7%). Conclusion: Baseline iPTH level is a good predictor of MWA efficacy for severe secondary hyperparathyroidism; parathyroidectomy is more effective for severe secondary hyperparathyroidism than MWA.
引用
收藏
页码:614 / 622
页数:9
相关论文
共 50 条
  • [31] US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study
    Fan, Bo-qiang
    He, Xiao-wei
    Chen, Huan-huan
    Zhang, Wei-ming
    Tang, Wei
    EUROPEAN RADIOLOGY, 2019, 29 (10) : 5607 - 5616
  • [32] Complications of microwave ablation in patients with persistent/recurrent hyperparathyroidism after surgical or ablative treatment
    Wei, Ying
    Zhao, Zhen-long
    Wu, Jie
    Cao, Shi-liang
    Peng, Li-li
    Li, Yan
    Yu, Ming-an
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2024, 41 (01)
  • [33] Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease
    Peng, Chengzhong
    Zhang, Zhengxian
    Liu, Jibin
    Chen, Hongyu
    Tu, Xiao
    Hu, Rihong
    Ni, Jun
    Weng, Ning
    Pang, Haisu
    Xue, Zhengmei
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (03): : 564 - 571
  • [34] Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism
    Wei, Ying
    Peng, Lili
    Li, Yan
    Zhao, Zhen-long
    Yu, Ming-an
    KOREAN JOURNAL OF RADIOLOGY, 2020, 21 (05) : 572 - 581
  • [35] Bone microarchitecture in patients undergoing parathyroidectomy for management of secondary hyperparathyroidism
    Ruderman, Irene
    Rajapakse, Chamith S.
    Opperman, Angelica
    Robertson, Patricia L.
    Masterson, Rosemary
    Tiong, Mark K.
    Toussaint, Nigel D.
    BONE REPORTS, 2020, 13
  • [36] Gender Differences Among Patients with Secondary Hyperparathyroidism Undergoing Parathyroidectomy
    Cheng, Shih-Ping
    Yang, Tsen-Long
    Lee, Jie-Jen
    Chen, Han-Hsiang
    Wu, Chih-Jen
    Liu, Tsang-Pai
    Liu, Chien-Liang
    JOURNAL OF SURGICAL RESEARCH, 2011, 168 (01) : 82 - 87
  • [37] Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
    Inaguma, Daijo
    Koiwa, Fumihiko
    Tokumoto, Masanori
    Fukagawa, Masafumi
    Yoneda, Shinji
    Yasuzawa, Hisami
    Asano, Kenji
    Hagita, Keiko
    Inagaki, Yosuke
    Honda, Daisuke
    Akizawa, Tadao
    CLINICAL KIDNEY JOURNAL, 2023, 16 (12) : 2614 - 2625
  • [38] Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism
    Koizumi, Masahiro
    Komaba, Hirotaka
    Nakanishi, Shohei
    Fujimori, Akira
    Fukagawa, Masafumi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (02) : 784 - 790
  • [39] A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
    Eddington, Helen
    Chinnadurai, Rajkumar
    Alderson, Helen
    Ibrahim, Sara T.
    Chrysochou, Constantina
    Green, Darren
    Erekosima, Ibi
    Hutchison, Alastair
    Bubtana, Abdalla
    Hegarty, Janet
    Kalra, Philip A.
    BMC NEPHROLOGY, 2021, 22 (01)
  • [40] Chronic dialysis patient with severe secondary hyperparathyroidism undergoing parathyroidectomy in Indonesia: a case series
    Nariswari, Adaninggar Primadia
    Tandarto, Kevin
    Aditiawardana
    BALI MEDICAL JOURNAL, 2023, 12 (02) : 2153 - 2159